Comparative Efficacy

FDA Unveils Long-Awaited Biosimilar Guidance to Accelerate Approvals and Cut Costs

1 month ago talkbio0Tagged Biopharmaceuticals, biosimilar guidance, biosimilarity, Clinical Research, Comparative Efficacy, draft guidance, Drug Costs, four-letter suffix, naming convention, United States Food and Drug Administration

FDA; biosimilar guidance; 2025 draft guidance; comparative efficacy study; analytical assessment; four-letter suffix; naming convention; biosimilarity; drug costs; biologic medicines

Lilly says further head-to-head trial data back Zepbound over Novos Wegovy

7 months ago talkbio0Tagged Comparative Efficacy, Obesity, semaglutide, SURMOUNT-5 Trial, tirzepatide, Weight Loss

Tirzepatide, Semaglutide, Weight Loss, Obesity Treatment, SURMOUNT-5 Trial, Comparative Efficacy

Comparative Efficacy of J&J’s Erleada and Astellas/Pfizer’s Xtandi in Non-Metastatic Prostate Cancer: Real-World Study Insights

1 year ago talkbio0Tagged apalutamide, Comparative Efficacy, enzalutamide, Erleada, Malignant neoplasm of prostate, nmCRPC, non-metastatic castration-resistant prostate cancer, profiles, Real-World Study, Safety

Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), Erleada (Apalutamide), Xtandi (Enzalutamide), Real-World Study, Comparative Efficacy, Safety Profiles